RSV Vaccine Significantly Reduces Severe Illness and Death in Adults, Studies Show

As winter approaches, a growing concern is the Respiratory Syncytial Virus (RSV), which can lead to severe illness and hospitalization, particularly in adults with underlying health conditions. While flu and COVID-19 vaccines are commonly discussed, RSV vaccines, recently introduced for adults, are often overlooked. Professor Liran Levi, a specialist in internal medicine and pulmonology at Sheba Medical Center, emphasizes the importance of including RSV vaccination in clinical discussions, especially for vulnerable populations like lung transplant recipients, where respiratory infections can be fatal.

RSV can manifest as a common cold but escalate to serious respiratory issues, exacerbating chronic lung diseases like asthma and COPD, and posing risks to individuals with cardiovascular conditions or weakened immune systems. In severe cases, hospitalization with oxygen or ventilation support may be necessary. Data from Israel highlights the severity, with 1,030 diagnosed RSV cases among those 60 and older in the 2025-2026 winter, resulting in 162 deaths within 30 days, a mortality rate of 15.7%.

The RSV vaccine is recommended for individuals aged 60 and above, as well as those aged 18-59 with increased risk factors. Recent studies, including the RESP-DK trial in Denmark and the CLEAR-VE study in the US, have demonstrated the vaccine's effectiveness. The RESP-DK study found that vaccinated individuals aged 60+ with COPD had no RSV hospitalizations or severe COPD exacerbations compared to unvaccinated groups, and no RSV-related deaths were recorded among the vaccinated.

The CLEAR-VE study, analyzing data from over 3.3 million adults, indicated that the vaccine was associated with a 57.6% lower risk of severe RSV-related COPD exacerbations and a 57.3% lower risk of severe RSV-related asthma exacerbations requiring hospitalization. Furthermore, the vaccine was linked to a 58.5% reduced risk of RSV-related cardiovascular events, including heart attack and stroke, and a 60.9% reduction in overall mortality when combined with other causes.

While these real-world data suggest a strong correlation between RSV vaccination and reduced severe outcomes, researchers caution that the studies do not prove causation and do not guarantee complete protection. Professor Levi urges adults, especially those with chronic lung or heart conditions or compromised immune systems, to discuss RSV vaccination with their doctors to determine individual suitability, considering age, health status, and current guidelines.